Physician profile
Roy Prashad
NPI 1760473573
$98,642.38
in general payments reported to CMS, 2019-2025
35 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $7,179 · 2021: $1,132 · 2022: $21K · 2023: $11K · 2024: $13K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $7,544 · Travel and Lodging: $2,528 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,900.00 |
| Food and Beverage | $7,543.63 |
| Travel and Lodging | $2,527.74 |
| Education | $164.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66,762.13 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $16,687.91 | 2019 | |
| Mallinckrodt Hospital Products INC. | $3,282.13 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $2,445.13 | 2019-2025 | Tremfya, Simponi Aria |
| Horizon Therapeutics Plc | $2,347.22 | 2019-2023 | Krystexxa |
| Amgen INC. | $1,822.25 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Pfizer INC. | $943.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $623.35 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $466.33 | 2019-2024 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $365.21 | 2022-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $311.26 | 2021-2025 | Saphnelo, Evusheld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.62 | 2019-2025 | Cyltezo, Ofev, Spevigo |
| Ucb, INC. | $259.55 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $246.97 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $244.24 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $201.00 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $170.51 | 2021-2025 | Strensiq |
| Sobi, INC | $167.05 | 2019-2025 | |
| Octapharma USA, INC. | $148.24 | 2024-2025 | Octagam Immune Globulin (Human) |
| Organon LLC | $146.84 | 2023-2025 | Hadlima |
| Aurinia Pharma U.S., INC. | $113.51 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $88.68 | 2019-2021 | |
| Radius Health, INC. | $74.73 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $72.77 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $51.96 | 2022 | |
| Medexus Pharma, INC. | $47.70 | 2019-2020 | |
| Genzyme Corporation | $43.16 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $42.26 | 2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $38.63 | 2019 | |
| Pacira Therapeutics, INC. | $33.74 | 2021 | |
| Celgene Corporation | $29.51 | 2019 | |
| Depuy Synthes Sales INC. | $28.18 | 2022 | |
| Tonix Medicines, INC. | $20.10 | 2025 | Tonmya |
| Fresenius Kabi USA, LLC | $20.05 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Prashad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.